Zoetis Inc. (ZTS) Stock

About Zoetis Inc.

Zoetis Inc. stands as a global leader in animal health, focusing on the research, development, manufacturing, and commercialization of veterinary pharmaceuticals, vaccines, and diagnostic tools. Its comprehensive portfolio serves a broad spectrum of species, encompassing both livestock, including cattle, swine, poultry, fish, and sheep, and beloved companion animals such as dogs, cats, and horses. Among its pharmaceutical offerings are various therapeutic agents. This includes vaccines, vital for preventing respiratory, gastrointestinal, and reproductive diseases by stimulating a targeted immune response; anti-infectives that combat or inhibit the proliferation of bacterial, fungal, or protozoal pathogens; and parasiticides aimed at eradicating both internal and external pests such as fleas, ticks, and various worms. Additional pharmaceuticals address areas such as pain management and sedation, anti-emesis, reproductive health, and oncology. The portfolio also features dermatological solutions for allergic skin conditions and atopic dermatitis, alongside medicated feed additives specifically designed for livestock. Beyond therapeutics, Zoetis offers an extensive array of diagnostic solutions. These include portable analysis systems for blood and urine, point-of-care testing devices, specialized instruments and reagents, rapid immunoassay kits, comprehensive reference laboratory services, and blood glucose monitoring equipment. Further extending its reach, the company provides supplementary offerings such as nutritional products, agribusiness support services, biodevices, genetic testing, and innovations in precision animal health. Zoetis distributes its diverse product portfolio to a broad customer base, including veterinary professionals, livestock producers, and retail channels. This distribution occurs directly via its sales representatives and technical specialists, as well as through partnerships with third-party veterinary distributors. Established in 1952, the company maintains its corporate headquarters in Parsippany, New Jersey.

Zoetis Inc. is led by CEO Kristin C. Peck, employs 13,800 people, headquartered in Parsippany, US, publicly traded since 2013.

Zoetis Inc. (ZTS) stock trades at $76.87 with a market capitalization of $32.23B. The stock is valued at a price-to-earnings (P/E) ratio of 13.58, price-to-book of 10.57, price-to-sales of 3.50. Over the past 52 weeks the stock has ranged between $71.52 and $161.77, and currently trades 52.5% below its 52-week high. It pays a dividend yielding 2.60%.

On profitability, Zoetis Inc. generates a return on equity (ROE) of 80.25% — well above the market average, a sign of a high-quality business, return on capital employed of 107.99%, an operating margin of 38.00%, a net profit margin of 27.79%.

In its most recent fiscal year, Zoetis Inc. reported annual revenue of $9.5B, net profit of $2.7B, revenue has compounded at 7.2% a year over the last five years, profit at 10.3% a year. Profit growing faster than revenue points to expanding margins.

The balance sheet shows a debt-to-equity ratio of 2.86 — a leveraged balance sheet worth monitoring, a current ratio of 3.03, total assets of $15.5B, $2.3B in cash and equivalents.

ZTS has an average daily trading volume of 7,484,552 shares, a beta of 0.74 (less volatile than the overall market).

Official website: www.zoetis.com